<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Major clinical trials for primary prevention of anthracycline-induced cardiotoxicity</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Major clinical trials for primary prevention of anthracycline-induced cardiotoxicity</h1>
<div class="graphic"><div class="figure"><div class="ttl">Major clinical trials for primary prevention of anthracycline-induced cardiotoxicity</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="20%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Citation</td> <td class="subtitle1">Study design</td> <td class="subtitle1">Type(s) of malignancy</td> <td class="subtitle1">Major findings</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Beta blockers</td> </tr> <tr> <td class="indent1">Kalay 2006<sup>[1]</sup></td> <td> <ul> <li>Randomized </li> <li>Single-blind </li> <li>Placebo-controlled </li> <li>Carvedilol 12.5 mg daily (n = 25) </li> <li>Placebo (n = 25) </li> </ul> </td> <td> <ul> <li>All </li> </ul> </td> <td> <ul> <li>Fewer deaths among those receiving carvedilol than placebo (one versus four, respectively). </li> <li>Those receiving carvedilol did not experience a significant decline in LVEF (70.5 to 69.7%, p = 0.3), while those receiving placebo did (68.9 to 52.3%, p = 0.001). </li> </ul> </td> </tr> <tr> <td class="indent1">Kaya 2013<sup>[2]</sup></td> <td> <ul> <li>Randomized </li> <li>Double-blind </li> <li>Placebo-controlled </li> <li>Nebivolol 5 mg daily (n = 27) </li> <li>Placebo (n = 18) </li> </ul> </td> <td> <ul> <li>Breast cancer </li> </ul> </td> <td> <ul> <li>Those receiving nebivolol did not experience significant worsening of echocardiographic parameters at six months while those receiving placebo did: <ul> <li>Mean LVEF (%): <ul> <li>Nebivolol: 65.6 <span style="font-size: 1.5em; padding-left: 0.1em; padding-right: 0.1em;">→</span> 63.8 </li> <li>Placebo: 66.6 <span style="font-size: 1.5em; padding-left: 0.1em; padding-right: 0.1em;">→</span> 57.5 </li> </ul> </li> <li>Mean LVEDD (mm): <ul> <li>Nebivolol: 47.0 <span style="font-size: 1.5em; padding-left: 0.1em; padding-right: 0.1em;">→</span> 47.1, p = 0.93 </li> <li>Placebo: 47.2 <span style="font-size: 1.5em; padding-left: 0.1em; padding-right: 0.1em;">→</span> 52.0, p = 0.01 </li> </ul> </li> <li>Mean LVESD (mm): <ul> <li>Nebivolol: 30.4 <span style="font-size: 1.5em; padding-left: 0.1em; padding-right: 0.1em;">→</span> 31.0, p = 0.20 </li> <li>Placebo: 29.7 <span style="font-size: 1.5em; padding-left: 0.1em; padding-right: 0.1em;">→</span> 33.4, p = 0.01 </li> </ul> </li> <li>Mean NT-proBNP (pmol/L): <ul> <li>Nebivolol: 147 <span style="font-size: 1.5em; padding-left: 0.1em; padding-right: 0.1em;">→</span> 152, p = 0.77 </li> <li>Placebo: 144 <span style="font-size: 1.5em; padding-left: 0.1em; padding-right: 0.1em;">→</span> 204, p = 0.01 </li> </ul> </li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1">Georgakopoulos 2010<sup>[3]</sup></td> <td> <ul> <li>Randomized </li> <li>Metoprolol (formulation not specified) (n = 42) </li> <li>Enalapril (n = 43) </li> <li>No additional treatment (n = 40) </li> </ul> </td> <td> <ul> <li>Lymphoma </li> </ul> </td> <td> <ul> <li>No difference in heart failure, LVEF, LVEDD, LVESD, or other echocardiographic parameters with metoprolol versus placebo. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Gulati 2016<sup>[4]</sup></td> <td> <ul> <li>Randomized </li> <li>Placebo-controlled </li> <li>Double-blind </li> <li>2 × 2 factorial </li> <li>n = 130 </li> <li>Metoprolol succinate (target dose 100 mg daily) (n = 58) </li> <li>Candesartan (target dose 325 mg daily) (n = 60) </li> </ul> </td> <td> <ul> <li>Breast cancer </li> </ul> </td> <td> <ul> <li>No significant effect on change in LVEF with metoprolol versus placebo (preliminary results). </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Angiotensin inhibitors (ACEIs/ARBs)</td> </tr> <tr> <td class="indent1">Georgakopoulos 2010<sup>[3]</sup></td> <td> <ul> <li>Randomized </li> <li>Metoprolol (n = 42) </li> <li>Enalapril (n = 43) </li> <li>No additional treatment (n = 40) </li> </ul> </td> <td> <ul> <li>Lymphoma </li> </ul> </td> <td> <ul> <li>No difference in heart failure, LVEF, LVEDD, LVESD, or other echocardiographic parameters with enalapril versus placebo. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Gulati 2016<sup>[4]</sup></td> <td> <ul> <li>Randomized </li> <li>Placebo-controlled </li> <li>Double-blind </li> <li>2 × 2 factorial </li> <li>n = 130 </li> <li>Metoprolol succinate (target dose 100 mg daily) (n = 58) </li> <li>Candesartan (target dose 325 mg daily) (n = 60) </li> </ul> </td> <td> <ul> <li>Breast cancer </li> </ul> </td> <td> <ul> <li>Those receiving candesartan did not experience a decline in LVEF (0.8, CI –0.4 to 1.9) while those receiving placebo did (2.6, CI 1.5-3.8, p = 0.026) (preliminary results of intention-to-treat analysis). </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Combined beta blockade and angiotensin inhibition</td> </tr> <tr class="divider_bottom"> <td class="indent1">Bosch 2013<sup>[5]</sup></td> <td> <ul> <li>Randomized </li> <li>Enalapril (target dose 10 mg twice daily) and carvedilol (target dose 25 mg twice daily) (n = 45) </li> <li>No additional treatment (n = 45) </li> </ul> </td> <td> <ul> <li>Hematologic malignancies </li> </ul> </td> <td> <ul> <li>Those receiving candesartan did not experience a decline in LVEF while those receiving placebo did (3.1% decrease, p = 0.035). </li> <li>Incidence of death or heart failure was lower in the enalapril/carvedilol arm compared with those receiving placebo (6.7 versus 22%, p = 0.036). </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Dexrazoxane</td> </tr> <tr class="divider_bottom"> <td class="indent1">van Dalen 2011<sup>[6]</sup></td> <td> <ul> <li>Meta-analysis (10 randomized controlled trials) </li> <li>Dexrazoxane (n = 799) </li> <li>Placebo (n = 285) </li> <li>No additional treatment (n = 535) </li> </ul> </td> <td> <ul> <li>Breast cancer </li> <li>Leukemia </li> <li>Other </li> </ul> </td> <td> <ul> <li>Risk of clinical heart failure was lower with dexrazoxane versus placebo (RR 0.18, CI 0.1-0.32, p&lt;0.001). </li> <li>No effect on overall survival. </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Statins</td> </tr> <tr> <td class="indent1">Acar 2011<sup>[7]</sup></td> <td> <ul> <li>Randomized </li> <li>Atorvastatin 40 mg daily (n = 20) </li> <li>No additional treatment (n = 20) </li> </ul> </td> <td> <ul> <li>Hematologic malignancies </li> </ul> </td> <td> <ul> <li>Those receiving atorvastatin did not experience worsening echocardiographic parameters while those receiving placebo did: <ul> <li>Mean LVEF (%): <ul> <li>Atorvastatin: 61.3 <span style="font-size: 1.5em; padding-left: 0.1em; padding-right: 0.1em;">→</span> 62.6 </li> <li>Control: 62.9 <span style="font-size: 1.5em; padding-left: 0.1em; padding-right: 0.1em;">→</span> 55.0 </li> <li>p value for comparison of mean change &lt;0.001 </li> </ul> </li> <li>Mean LVEDD (mm): <ul> <li>Atorvastatin: 46.5 <span style="font-size: 1.5em; padding-left: 0.1em; padding-right: 0.1em;">→</span> 46.3 </li> <li>Control: 47.2 <span style="font-size: 1.5em; padding-left: 0.1em; padding-right: 0.1em;">→</span> 49.2 </li> <li>p value for comparison of mean change = 0.021 </li> </ul> </li> <li>Mean LVESD (mm): <ul> <li>Atorvastatin: 30.9 <span style="font-size: 1.5em; padding-left: 0.1em; padding-right: 0.1em;">→</span> 29.6 </li> <li>Control: 30.3 <span style="font-size: 1.5em; padding-left: 0.1em; padding-right: 0.1em;">→</span> 32.3 </li> <li>p value for comparison of mean change &lt;0.001 </li> </ul> </li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1">Seicean 2012<sup>[8]</sup></td> <td> <ul> <li>Retrospective </li> <li>Observational </li> <li>Statin prescribed for other indication (n = 67) </li> <li>Propensity-matched controls (n = 134) </li> </ul> </td> <td> <ul> <li>Breast cancer </li> </ul> </td> <td> <ul> <li>Risk of heart failure hospitalization was lower for those receiving a statin than those receiving placebo (HR 0.3, CI 0.1-0.9, p&lt;0.03). </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">LVEF: left ventricular ejection fraction; LVEDD: left ventricular end-diastolic diameter; LVESD: left ventricular end-systolic diameter; NT-proBNP: N-terminal pro B-type natriuretic peptide; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker; CI: confidence interval; RR: relative risk; HR: hazard ratio.</div><div class="graphic_reference">References: 

<ol>
<li>Kalay N, Basar E, Ozdogru I, et al. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy. J Am Coll Cardiol 2006; 48:2258.</li>
<li>Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol 2013; 167:2306.</li>
<li>Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol 2010; 85:894.</li>
<li>Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 2016; 37:1671.</li>
<li>Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013; 61:2355.</li>
<li>van Dalen EC, Caron HN, Dickinson HO, and Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2011; :CD003917.</li>
<li>Acar Z, Kale A, Turgut M, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2011; 58:988.</li>
<li>Seicean S, Seicean A, Plana JC, et al. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol 2012; 60:2384.</li></ol></div><div id="graphicVersion">Graphic 118433 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
